INTRODUCTION
The cell cycle in mammalian cells consists of four phases, G 1 , S, G 2 and M, which govern cell fate, allowing the formation of two fully functional daughter cells.
The first evidence of the molecular basis underlying cell division arose more than 20 years ago, from studies involving both budding and fission yeast (for review article see 1). After discovering cdc2 (cell division cycle 2) in Schizosaccaromyces pombe and CDC28 in Saccharomyces cerevisiae, in 1987 two different research groups characterized the human homologue of these yeast regulatory proteins, which was collectively referred as to cdc2 (2, 3) . Since that time, a multitude of cdc2-related kinases have been cloned based on sequence and functional similarity, and functionally characterized as having distinct roles in cell cycle control. Cdks, cyclin-dependent kinases, are the catalytic subunits of complexes whose regulatory subunits are the cyclins. They are a family of proteins named for their cyclic expression and degradation and they play an important role in regulating cell division. Cyclins are synthesized immediately before they are used and their levels fall abruptly after their action because of degradation through ubiquitination (4) . Interaction between the cyclins and the cdks occurs at specific stages of the cell cycle, and their activities are required for progression through the cell cycle. Unlike the cyclins, the protein levels of the cdks do not oscillate throughout the cell cycle, allowing the cdks to be present in an inactive form until the formation of complexes with the cyclins (4).
The current model explaining cell cycle involves cyclin-cdk complexes that, by phosphorylating different substrates, govern not only cell division, but also several cellular pathways such as signal transduction, differentiation and apoptosis. One of the best examples to present a new dimension of the concept of cyclin/cdk complexes is cdk9 and its related T cyclins (T1, T2a and T2b) and cyclin K. Cyclin-dependent kinase 9 (cdk9) is a cdc2-related serine/threonine kinase previously named PITALRE, which was isolated using degenerate oligonucleotide primers derived from conserved regions found in cdc2 and cdk2 (5) . The deduced amino acid sequence is 47% identical to that of CHED kinase involved in cell cycle control in hematopoietic cells (6) and it is 42% identical with the Saccharomyces cerevisiae SGV1 gene product, a kinase involved in the pherormone response pathway (5) . The cdk9 gene is widely expressed in human and murine tissues with higher levels found in terminally differentiated cells and, in muscle cells, its promoter activity parallels the protein levels (7, 8, 9) . The regulatory units of cdk9 are the T-family cyclins (T1, T2a and T2b) and cyclin K (10) . Cyclin T1 and cyclin T2 mRNAs are widely expressed in adult human tissues with higher levels in the muscle, spleen, thymus, testis, ovary and peripheral blood lymphocytes. In HeLa nuclear extracts, roughly 80% of cdk9 is complexed with cyclin T1 and 10% with cyclin T2a and cyclin T2b (11, 12) . Cyclin K is ubiquitously expressed in adult mouse and human tissue, but is most abundant in developing germ cells of adult testes and ovaries (13) . The elevated levels of cdk9 and its regulatory subunits (cyclins T1 and T2) in terminally differentiated cells, together with the fact that cdk9/cyclinT complexes are not cell cycle-regulated, distinguish cdk9 from the other cdks (1, 4) . Moreover, unlike the other cdks, which regulate cell cycle progression and phosphorylate histone H1, cdk9 fails to phosphorylate H1. Notably, cdk9 phosphorylates in vitro the C-terminus of pRb, the protein product of the Retinoblastoma gene, showing a phosphorylation pattern involving only Ser residues (5, 7, Simone et al., submitted). Other in vitro substrates of cdk9 include casein and MBP (Myelin Basic Protein) (5) . As cyclin T levels are not cell cycle-regulated, cdk9 kinase activity does not change during the different phases of the cell cycle. The catalytic activity of the cdk9 immunocomplex results only from cdk9 and it is abolished using a kinase inactive mutant that behaves as a dominant negative form (cdk9dn) (4) . This consists of a point mutation within the ATP binding domain that changes the Asp to Asn at residue 167. In addition to these data, colony formation assay performed using several cell lines demonstrated that cdk9dn does not reduce cell growth compared to a mock control, if cdc2dn arrests cells in G 2 (Simone et al., unpublished results).
All of these characteristics of cdk9/cyclin function confirm the new concept of a multifunctional cyclindependent kinase. This is not the first cdk/cyclin complex to not be involved in the cell cycle; in fact, cdk7/cyclin H, forming TFIIH, cdk8/cyclin C, involved in transcription, and cdk5/p35, active during neural differentiation, confirm the idea of a multifunctional kinase.
CDK9-INTERACTING PROTEINS
Immunoprecipitation experiments using anti-cdk9 antibodies have shown that cdk9 co-immunoprecipitates with several proteins. Some of them are now well-known and their identification has given us the opportunity to better understand the function of cdk9 immunocomplexes.
In our lab in 1998, MacLachlan et al. used a yeast two hybrid system to identify TRAF2 (a cytoplasmic tumor necrosis factor signal transducer) as a cdk9-interacting protein, suggesting a role for cdk9 in the TNF signal transduction pathway. Cdk9 interacts with a conserved domain in the TRAF-C region of TRAF2, a motif that is known to bind other kinases responsible for TRAFmediated signaling (14) (Fig 1A) . This finding is relevant because it represents a new link between cdk9 and HIV infection due to the involvement of NFkB in both the TNF pathway and HIV genome-activated transcription. The relevance of this interaction is further supported by data on TRAF2 knock-out mice which are defective in the ability to protect skeletal muscle cells against apoptosis. Finally, that report implicated a role of cdk9 in the cytoplasm. In the first studies, cdk9 was characterized as a nuclear protein (5), but Western blotting of nuclear and cytoplasmic extract in human and rodent cells confirmed that the kinase is present in both subcellular compartments (Simone et al., unpublished results).
Two years later, we demonstrated cdk9-B-Myb binding by identifying a mechanism in which cdk9 could inhibit B-Myb autoregulation (15) (Fig 1B) . This is interesting because it further suggests that cdk9 could be involved in the signaling pathways that promote differentiation and inhibit cell cycle progression and DNA synthesis.
More recently, O'Keeffe et al. described other cdk9-associated proteins through affinity purification of the immunocomplex in human cells. They demonstrated that cdk9 could be present in the cell in at least three major complexes in addition to free cdk9 and that it requires the interaction with the kinase-specific chaperone pathway. In light of this observation, it seems that the pathway involving the sequential actions of Hsp70 and Hsp90/Cdc37 may be used for cdk9 folding and cdk9/cyclin T1 assembly. In an initial step, newly translated cdk9 may be bound by Hsp70, which acts to stabilize cdk9 and to assist the correct folding of the nascent polypeptide. Once cdk9 has reached a certain folded state, Hsp70 may mediate its transfer to Hsp90/Cdc37. This kinase-specific chaperone complex probably establishes and maintains the cdk9 molecule in a state that can readily form a complex with cyclin T1 during the final stage of the assembly process. When many cdk9 proteins are moving along this pathway to eventually become part of the mature cdk9/cycT1 complex, a major portion of cdk9, either translated without the protection of Hsp70 or dissociated from the chaperones along the pathway, is rapidly degraded in the cell. Finally, among the three major cdk9 complexes, only the cdk9/cyclin T1 dimer contains all the activities attributed to P-TEFb. The two chaperone-cdk9 complexes are important precursors that are essential for the generation of the mature and active cdk9/cyclin T1 P-TEFb complex (16) (Fig 1C) .
Finally, we characterized the physical interaction between cdk9, cyclin T2 and pRb, and found that the Cterminus of pRb (835-928) directly interacts with the region surrounding the kinase domain of cdk9 (129-195) and with both isoforms of cyclin T2 (a and b), suggesting that the region of interaction involves the common sequence 1-642 aa. In addition, cdk9 complexes phosphorylate the Cterminus of pRb (793-928) in vitro and our data suggest that the phosphorylated region spans the amino acids 793-834 (Simone et al., submitted; Fig 1D) . This evidence is intriguing because it confirms the division of the pRb Cterminus into two subdomains. In fact, several groups have reported that the pRb C-terminus (793-928) can be separated into two subdomains with specificity for cdk/cyclin complexes. The first region (793-829) contains (17, 18, 19) . During the cell cycle, pRb phosphorylation mediated by cdk/cyclin complexes is required for the cell to progress through the different phases. Several pieces of evidence could help explain the meaning of cdk9-mediated phosphorylation of pRb in vivo. First, pRb has been identified to functionally interact with factors which influence RNA polymerase IIdependent gene transcription (20, 21). This important effect of pRb on RNA pol II transcription could represent a functional link with PTEF-b, and cdk9 phosphorylation of pRb could be a signal involved in transcriptional control. The second point of interest is the involvement of pRb during cellular differentiation and in terminally differentiated cells, which we will discuss hereafter.
CDK9 AND TRANSCRIPTION
It is now widely accepted that a large number of periodically expressed genes are regulated at the transcriptional level during specific stages of the cell cycle by the concerted action of appropriate transcription repressors and/or activators (22).
Recent data indicate a role for cdk complexes in regulating transcription by functional and physical interaction with components of the basal transcription apparatus (23). Three different cdks (cdk7, cdk8 and cdk9) appear to have a role in basal transcription. Indeed, all three cdks have been reported as being capable of mediating catalytic hyperphosphorylation of the carboxy-terminal domain (CTD) of RNA polymerase II (RNA pol II). A number of studies have underlined the importance of CTD phosphorylation in transcription (22). The CTD of RNA pol II molecules present in the pre-initiation complexes (PIC) is unphosphorylated (RNA pol IIa), whereas phosphorylated CTD is a hallmark of active elongating polymerase (RNA pol IIb) complexes (24). It has also been proposed that CTD phosphorylation is critical for the release of the PIC complex from the promoter by distruption of contacts between the CTD and transcriptional mediator and/or other basal factors, such as TBP, which is absent in the elongation complex (22).
Transcription in eukaryotic cells involves three major steps: initiation, elongation and termination. It has been thought that regulation occurs primarily at the level of the initiation step. It is now recognized that transcription elongation is a critical step for regulation of gene expression (25, 26, 27). Shortly after initiation, RNA pol II faces a barrier of negative transcription elongation factors (N-TEF) and enters abortive elongation. The action of positive transcription elongation factors (P-TEF) lowers the barrier of N-TEF and allows the transition into productive elongation producing longer mRNA transcripts (28). Two N-TEFs have recently been identified and characterized: DSIF (DRB-sensitivityinducting factor) and NELF (negative elongation factor). DSIF, composed of Spt5 (p160) and Spt4 (p14), and NELF, composed of five polypeptides (NELF-A to -E), functionally cooperate to strongly repress RNA pol II elongation (28). The factors that positively regulate the elongation step form an essential multiprotein complex named P-TEFb. P-TEFb was originally identified in Drosophila and mammals and it is composed of two subunits: the catalytic subunit cdk9 and the regulatory subunit cyclin T1 (29) (Fig 1E) .
In Drosophila cells, it has been demonstrated that the direct recruitment of a Gal4-binding domain PTEFb hybrid to an hsp70 promoter is sufficient to activate transcription. Mutational studies have shown that this stimulation depends on cdk9 kinase activity and on cdk9 interaction with cyclin T. These results, coupled with the frequent colocalization of p-TEFb and the hypophosphorylated form of RNA pol II found at promoter-pause sites, support a model in which P-TEFb acts to stimulate promoter-paused RNA pol II to enter into productive elongation (30) . It has also been demonstrated that P-TEFb regulates transcriptional elongation through cdk9 phosphorylation of Spt5, one of the two subunits of DSIF (31, 32, 28) . It is a highly conserved protein that, with Spt4 and Spt6, can regulate transcriptional elongation in both a positive and a negative manner, and it has two important domains that are involved in transcriptional control. The Spt5 domains that bind Spt4 and RNA pol II in addition to the CTR1 domain, a C-terminal repeat element, are critical for mediating DRB (ATP analogue 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole) inhibition and Tat activation. P-TEFb phosphorylates the CTR1 domain of SPT5, suggesting that P-TEFb phosphorylation of both RNA pol II and Spt5 may be critical for the regulation of transcriptional elongation (31, 32, 28) .
In mammalian cells, targeted recruitment of cdk9/cyclin T1 to specific promoters stimulates transcription in vivo (33) . Transcriptional enhancement is dependent on active cdk9, as the catalytically inactive form has no transcriptional effect. It has been demonstrated that, unlike conventional activators, DNAbound cdk9 does not activate enhancerless TATApromoters unless TBP is overexpressed, suggesting that cdk9 acts in vivo at a step subsequent to DNA-bound TFIID recruitment. Finally, it has been determined that cdk9-mediated transcriptional activation is mediated by preferentially stimulating productive transcription elongation (33) . In addition it has been found that cdk9/cyclin T1-mediated transcription requires CTDcontaining RNA pol II, suggesting that the CTD is the major target of the cdk9/cyclin T complex in vivo. Unlike cdk7 and cdk8, the other two cdks that are able to phosphorylate the CTD in vitro, only the cdk9 complex activates gene expression in a catalyticdependent manner. Finally, unlike cyclin T1 and cyclin T2, the targeted recruitment of cyclin K to promoter DNA does not stimulate transcription in vivo (34) . Collectively, these data strongly indicate that the PTEFb kinase subunits-cdk9/cyclin T complex is specifically involved in transcription and the CTD domain of RNA pol II is the major functional target of this complex in vivo. In addition, PTEF-b has been demonstrated to localize throughout the non-nucleolar nucleoplasm, especially in the nuclear speckles, subnuclear structures that are associated with increased concentrations of factors involved in transcription and pre-mRNA splicing (35) .
How cellular promoters recruit specific kinase complexes to RNA pol II remains to be investigated. The ability of cdk9/cyclin T to function in a catalyticdependent manner when bound to the upstream promoter sequences raises the possibility that promoterspecific activation of transcription elongation might occur through interaction between cdk9/cyclin T and a dedicated DNA-bound activator. Recent studies suggest that cdk9/cyclin T complex may be recruited to specific promoters by cellular transcription factors that bind to the promoter sequences of genes regulated at the level of transcriptional elongation. This is the case of HIVTat-mediated and MyoD-mediated transcription, two aspects of cdk9 function that we analyze in the next two sections.
CDK9 AND HIV INFECTION
The transcriptional activator protein (Tat) of HIV-1 enhances synthesis of viral RNA recognizing TAR, a hairpin loop structure near the 5' end of the viral RNA, and stimulating RNA pol II processivity, thus causing an increase in the fraction of transcripts that extend all the way to the 3' end of the provirus (36) . The link between Tat and transcriptional activation has been identified in a complex which exerts a kinase activity on the CTD of RNA pol II. This complex is composed at least of cdk9 and cyclin T1. Cdk9 was identified independently as a kinase that binds the activation domain of Tat in vitro and phosphorylates RNA pol II (37). Cyclin T was identified as a protein that binds to a Tat affinity resin (11) . The important role of cdk9/cyclin T was demonstrated by its immunodepletion from transcription extracts, which was found to inhibit activation by Tat as well as basal transcription (29, 38, 11) . The interaction between Tat and cdk9/cyclin T is mediated by cyclin T-Tat physical binding. Cyclin T-Tat complex binds TAR with higher affinity than Tat alone, thereby identifying in cyclin T the host-cell factor that allows HIV infection of human cells. Cyclin T1 fulfills the criteria for the species-specific host-cell factor: the human gene maps on chromosome 12, which was identified as the human locus for Tat cofactor, and its over-expression in HIV infection nonpermissive rodent cells is sufficient to permit Tat activation (39, 40, 36). One study on human-rodent hybrid complexes showed that stable complexes containing human cyclin T1 and human or rodent cdk9 supported Tat transcription, while rodent cyclin T1 and human cdk9 failed to interact with Tat and to mediate Tat transactivation (41) (Fig 1F) . Interestingly, it seems that only human cyclin T1 cooperates with Tat; in fact, Tat transactivation in rodent cells occurs in the presence of hcyclin T1 but not in the presence of hcyclin T2. Overexpression of hcyclin T2 inhibits Tat function in both rodent and human cells (42). The difference in Tat transactivation between the two T cyclins confirms the idea of different roles for cdk9 kinase activity in several cellular processes depending on its interaction with cyclins. Cdk9/cyclinT1-Tat complex is regulated by positive and negative signals that start from the complex itself and from other cofactors. The acetyltransferases p300 and PCAF directly acetylate Tat on two different functional domains. p300 acetylates Lys 50 in the TAR RNA binding domain and PCAF acetylates Lys 28 in the activation domain of Tat. Acetylation at Lys 28 by PCAF enhances Tat binding to cdk9/cyclin T1, while acetylation by p300 at Lys 50 promotes the dissociation of Tat from TAR RNA that occurs during early transcriptional elongation. These data suggest that acetylation of Tat regulates two functionally critical steps in cdk9/cyclin T1-Tat-mediated transcription (43). Another mechanism that regulates the activity of the complex depends on the ability of Tat to modify the substrate specificity of cdk9/cyclin T1. In the absence of Tat, cdk9 and cdk7 phosphorylate the CTD on two serines, Ser 2 and Ser 5, respectively. In the presence of Tat, the substrate specificity of cdk9 is altered, such that the kinase phosphorylates both Ser 2 and Ser 5 of CTD RNA pol II instead of phosphorylating only Ser 2. The CTD phosphorylation state indicates a biphasic modification pattern and the second phase is Tat-and TAR-dependent and is sustained by cdk9 only (44) ( Fig  1F) . In addition, cdk9/cyclin T1 complex is intrinsically incapable of forming a stable complex with Tat and TAR due to two built-in autoinhibitory mechanisms in P-TEFb. Both mechanisms exert little effect on the cdk9/cyclin T1-Tat interaction, but prevent the P-TEFbTat complex from binding to TAR RNA. The first autoinhibition arises from the unphosphorylated state of cdk9, which establishes a P-TEFb conformation that is unfavorable for TAR recognition. Autophosphorylation of cdk9 overcomes this inhibition by inducing conformational changes in P-TEFb, thereby exposing a region in cyclin T1 for possible TAR binding. An intramolecular interaction between the N-and Cterminal regions of cyclin T1 sterically blocks the PTEFb-TAR interaction and constitutes the second autoinhibitory mechanism. This inhibition is relieved by the binding of the C-terminal region of cyclin T1 to the transcription elongation factor Tat-SF1 and perhaps other cellular factors. Upon release from the intramolecular interaction, the C-terminal region also interacts with RNA pol II and is required for HIV-1 transcription, suggesting its role in bridging the cdk9/cyclin T1-Tat-TAR complex and the basal elongation apparatus (45, 46) (Fig 1F) . Finally, Sune and colleagues characterized the protein components of kinase activity present in HeLa cell nuclear extracts. They found the presence of cyclin T1, cdk9, Tat-SF1 and at least three unidentified proteins (47) (Fig 1F) . These data indicate that the transcriptional regulation of HIV infection is still unclear and that more studies are awaited to further define the molecular mechanism underlying cdk9/cyclin T1-Tat interaction and functional regulation.
CDK9 AND CELLULAR DIFFERENTIATION
The difference between cdk9 and the cdks involved in the regulation of the cell cycle might also reflect a different function during terminal differentiation. In addition, the role of cyclin T2 a and b isoforms in regulating cdk9 activity is still unknown. We have investigated cdk9 function in a paradigmatic differentiation model: a skeletal muscle differentiation system. In this context, the induction of myocyte differentiation upon serum withdrawal is accompanied by the down-regulation of cyclins D1, E and A and the up-regulation of several cdk inhibitors, which lock the cyclin-cdk complexes in an inactive form. This allows exit from the cell cycle and the expression of musclespecific genes (48). Transcription of genes that characterize the phenotypic and biochemical identity of differentiated muscle cells is activated by myogenic basic helix-loop-helix (bHLH) transcription factors. These are the myogenic regulatory factors (MRFs) MyoD, Myf5, myogenin and MRF4. They operate by heterodimerizing with the E2A gene products (E12 and E47) via the HLH domain and by binding to certain recognition sites (E-box -> CANNTG) in the regulatory regions of muscle-specific genes (49, 50, 51) . Overexpression of cdk/cyclins has been reported to inhibit the activity of MyoD and prevent myogenic differentiation by different modalities. Overproduction of cyclins E and A together with their associated kinase, cdk2, impinge on MyoD function by virtue of their ability to phosphorylate pRb (52, 53) , an essential cofactor for MyoD-dependent transcription (54, 55) . In addition, cdk2 and cdc2 can inactivate MyoD function by phosphorylating Ser 200, thereby triggering MyoD degradation (56, 57) . Cyclin D1 overexpression inhibits myogenic differentiation by promoting the nuclear accumulation of cdk4, which in turn binds the Cterminus of MyoD and prevents MyoD DNA binding and activation of myogenic transcription (58, 59) . Our studies have shown that overexpression of cdk9/cyclin T2a, unlike other cdk/cyclin complexes, enhances MyoD function and promotes myogenic differentiation, while inhibition of cdk9 kinase activity by a dominant negative form prevents the activation of the myogenic program. The N-terminal region of cdk9 and full-length cyclin T2a directly interact with the bHLH region of MyoD, allowing the formation of a complex that stimulates transcription of specific muscle genes (Simone et al., manuscript in preparation) (Fig 1G) .
Cdk9 involvement in the differentiation program is supported by recent studies. First of all, cdk9 is involved in transcriptional elongation of many, but not all, genes in Drosophila cells (30) and, in human cells, controls histocompatibility class II (MHC II) genes (60), but not CD96, CD25 or IL-2 genes (61), suggesting a role of cdk9 complexes in specific transcription of targeted promoters. In addition, P-TEFb is activated differentially in lymphocytes and monocytes. In fact, cdk9/cycT1 activation in peripheral blood lymphocytes (PBLs) involves an increase in mRNA and protein levels of both proteins (62); conversely, differentiation of promonocytic cells involves only cycT1 protein levels through posttranscriptional modifications (63) . In monocytes/macrophages, the overexpression of cdk9dn blocks the differentiation program rendering U937 cells sensitive to apoptosis (61) . The involvement of the kinase activity of cdk9 in monocyte differentiation reflects its involvement in the myogenic program. In mouse myoblasts, the overexpression of cdk9dn inhibits muscle gene transcription and promotes cell death (Simone et al., manuscript in preparation).
How cdk9/cyclin T2a enhances MyoD trancriptional activity is still the subject of study, but the cdk9/cyclin T1-Tat complex could give us several research inputs. Data regarding the involvement of the HAT proteins, essential cofactors of MyoD-mediated transcription, in Tat-mediated transcription; the role of cdk9 in the transcriptional elongation complex; the physical interaction between MyoD and cyclin T2a; and cdk9 phosphorylation of MyoD in vitro support the Tatlike model in which cdk9 recruitment on myogenic promoters is mediated by MyoD and allows transcriptional elongation. The intricate regulation of Tat complex could suggest that cdk9/cyclin T2a-MyoD complex has several positive and negative regulating signals and one of them could be the cdk9 phosphorylation of MyoD.
Several pieces of evidence have implicated pRb as an essential cofactor during muscle differentiation. Muscle cells derived from pRb-/-mice fail to irreversibly exit the cell cycle (64), express reduced levels of late differentiation markers and display impaired fusion into multinucleated myotubes (55) . Several hypotheses have been proposed to justify pRb involvement in differentiation, including a physical binding with MyoD (54) and the inhibition of the antimyogenic activity of E2F (65, 66, 67) . More recently, pRb has been shown to promote functional synergism between MyoD and MEF2 protein, a coactivator of specific gene transcription (68) . However, the molecular mechanisms through which pRb promotes myogenic transcription remain unclear. We found that cdk9/cycT2 binds and phosphorylates the C-terminus of pRb (Simone et al., submitted). Immunoprecipitated cdk9 complexes from C2C12 mouse myoblasts induced to differentiate have an increasing kinase activity on p56/pRb with a peak of phosphorylation at 96 h of the myogenic program (8) . During muscle differentiation, pRb is present in the active hypophosphorylated form, especially due to down-regulation of cyclins A, E and D1 and the up-regulation of cdk inhibitors (69). It is possible that cdk9/cycT2 kinase activity is involved in the basal phosphorylation of the retinoblastoma protein and that pRb and cdk9/cycT2 cooperate to support MyoD-mediated myogenic transcription.
In addition, the MyoD region of interaction with cdk9 is the bHLH domain. This is a conserved region in the bHLH family of transcription factors and several of them are involved in transcriptional regulation of the differentiation program. It will be interesting to study the action of cdk9/cycT2a on bHLH transcription factors in other models of differentiation.
CONCLUSION
All the data discussed in this review have opened several fields of research in basic molecular biology, tumorigenesis, HIV infection disease and differentiation, but the one concept emphasized herein is the idea of a gene codifying for a kinase that exerts several functions in different subcellular compartments, the idea of a multifunctional kinase.
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